Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

Journal of cachexia, sarcopenia and muscle - 1 Dec 2018

Kandarian Susan C, Nosacka Rachel L, Delitto Andrea E, Judge Andrew R, Judge Sarah M, Ganey John D, Moreira Jesse D, Jackman Robert W

Abstract excerpt

BACKGROUND: Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was responsible for atrophy in treated myotubes. In the present study, we tested whether C26 tumour-derived LIF is required for cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cachexia
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia Inhibitory Factor

Share to Morbidity

Share to Muscle Fibers, Skeletal

Share to Muscle, Skeletal

Share to Organ Size

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30270531
DOI: 10.1002/jcsm.12346
PMCID: PMC6240747

Genes

LIF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.PMID 30270531Read ↗

A Multiomic Analysis of Cachectic Mice Reveals Cancer Driven Suppression of Muscle Stem Cell DifferentiationSemantic proximity Read ↗

Proteomics analysis of C2C12 myotubes treated with atrophy inducing cancer cell-derived factorsSemantic proximity Read ↗

Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.Semantic proximity Read ↗

TCF7L2 is a master regulator of muscle wasting in severe cancer cachexiaSemantic proximity Read ↗

The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells.Semantic proximity Read ↗

MicroRNA-mRNA Co-sequencing Identifies Transcriptional and Post-transcriptional Regulatory Networks Underlying Muscle Wasting in Cancer CachexiaSemantic proximity Read ↗

Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexiaSemantic proximity Read ↗

<i>Drosophila</i> larval models of invasive tumourigenesis for in vivo studies on tumour/peripheral host tissue interactions during cancer cachexiaSemantic proximity Read ↗

Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for InflammationSemantic proximity Read ↗

Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexiaSemantic proximity Read ↗

Repression of the Wnt pathway effector TCF7L2 reverses lethal cachexia in mice with intestinal cancersSemantic proximity Read ↗

JAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food IntakeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.